MNG126
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.385
- CHOLESTEROL_HOMEOSTASIS+0.349
- NOTCH_SIGNALING+0.192
- WNT_BETA_CATENIN_SIGNALING+0.180
- PANCREAS_BETA_CELLS+0.173
- BILE_ACID_METABOLISM+0.165
- ESTROGEN_RESPONSE_EARLY+0.162
- KRAS_SIGNALING_DN+0.152
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.150
- TGF_BETA_SIGNALING+0.109
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.434
- OXIDATIVE_PHOSPHORYLATION-0.353
- ALLOGRAFT_REJECTION-0.350
- INFLAMMATORY_RESPONSE-0.338
- G2M_CHECKPOINT-0.281
- MYC_TARGETS_V1-0.274
- INTERFERON_GAMMA_RESPONSE-0.256
- MTORC1_SIGNALING-0.243
- E2F_TARGETS-0.239
- KRAS_SIGNALING_UP-0.207
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 38aa467f-bd67-475e-9280-7e710bdc0cb3 | — | — | 0.762 |
| 2 | MNG290 | — | — | 0.761 |
| 3 | MNG1264 | — | — | 0.760 |
| 4 | MNG965 | — | — | 0.749 |
| 5 | SRR11296877 | — | — | 0.745 |
| 6 | MNG660 | — | — | 0.737 |
| 7 | TCGA-A8-A09B-01A-11R-A00Z-07 | — | B | 0.733 |
| 8 | TCGA-B6-A0RQ-01A-11R-A115-07 | — | A | 0.733 |
| 9 | SRR8613741 | — | F | 0.731 |
| 10 | BS_AD4JPN9Q | Ganglioglioma | — | 0.724 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.385 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.349 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.192 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.173 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.165 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.162 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.152 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.109 | Inavolisib | — uncovered |
| MYOGENESIS | 0.106 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.087 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.081 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.081 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.075 | Temsirolimus | — uncovered |
| COAGULATION | 0.056 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.051 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.041 | Inavolisib | — uncovered |
| APOPTOSIS | 0.039 | Idelalisib | — uncovered |